

Thiopurine May Prevent Colon Cancer in IBD

BY MICHELE G. SULLIVAN

CHICAGO — Thiopurine therapy appears to prevent colorectal neoplasias in patients with long-term, extensive inflammatory bowel disease, reducing the risk of cancer or high-grade dysplasia by more than 70%.

The finding from a large French prospective cohort study casts a new light on the usual concern about the immunosuppressive effect of thiopurine, Dr. Philippe Seksik said at the annual Digestive Disease Week.

“Thiopurines could increase the risk of colorectal cancer via their immunosuppressive effect, or through their anti-inflammatory effect, [they] could reduce the risk of colorectal cancer,” said Dr. Seksik of Saint-Antoine Hospital, Paris. “Our data raise the hypothesis that the anti-inflammatory effect of thiopurines

long-standing colitis, there were five colorectal cancers and one case of high-grade dysplasia.

The investigators performed a multivariate analysis examining the risk of colorectal neoplasia associated with sex, age, disease duration, and extensive colitis. The presence of extensive colitis significantly increased patients' risk of neoplasia sevenfold, compared with the expected number of cases obtained from

the national French cancer registries.

When the team examined the association between thiopurine therapy and neoplasia, they found a nonsignificant risk reduction of 43%, compared with patients who had never taken a thiopurine. The effect was much more powerful when the analysis was restricted to those with long-standing extensive colitis; thiopurine exposure reduced the risk of new neoplasia by 72%—a 3.5-fold

decrease from the rate seen in thiopurine-naïve patients.

Researchers are still uncertain about the mechanism of protection, Dr. Seksik said. “The protective effect could be due to a nonspecific anti-inflammatory effect, or it could be a drug-specific, antineoplastic action on the inflammation-dysplasia-cancer sequence.”

Dr. Seksik reported that he had no relevant financial disclosures. ■



In those with long-standing extensive colitis, thiopurine reduced the risk of new neoplasia by 72%.

DR. SEKSIK

on colonic mucosa has a much greater impact on the risk of colorectal cancer than the putative deleterious effect of its drug-induced immunosuppression.”

Dr. Seksik and his colleagues examined the risk of colorectal cancer in CESAME, a cross-sectional French cohort study that prospectively assesses the risk of cancers in patients with irritable bowel diseases. The study recruited 19,500 patients from 2004 to 2005, and followed them through December 2007.

The patients' mean age at recruitment was 40 years (range, 1-96 years). The mean duration of the disease was 8 years, although again, the range was very wide, including a disease duration of up to 65 years. In all, 11,760 patients (60%) had Crohn's disease; of these, 15% had long-standing extensive colitis, defined as a disease duration of more than 10 years with more than 50% of the colonic mucosa involved. The remaining 40% of the cohort had ulcerative colitis or an unclassified inflammatory bowel disease; of these, 37% had long-standing extensive colitis.

In the entire cohort, there were 36 incident cases of colorectal cancer and 21 high-grade dysplasias. Among only those patients with long-standing extensive colitis, there were 21 new cancers and 8 high-grade dysplasias.

At study inclusion, 36% of the patients were on immunosuppressive therapy. Of those, 30% were taking azathioprine or 6-mercaptopurine, 4% were taking methotrexate, and 5% were taking a tumor necrosis factor antagonist. Among all thiopurine-exposed patients, there were nine incident cases of colorectal cancer and three cases of high-grade dysplasia. Among only those with

Boston University School of Medicine

and

Pediatric News / Family Practice News

JOINTLY SPONSOR

Pediatric Infectious Diseases in the Headlines

A Continuing Medical Education Conference

October 24 – 25, 2009
Royal Sonesta Hotel, Cambridge, MA

Topic Highlights:

- **What Is The Diagnosis?** with James H. Brien, DO
- **Influenza Challenges: Diagnosis, Treatment, Resistance, and Immunization**
- **CaMRSA – Diagnosis, Treatment, and Prevention**
- **Otitis Media – Is There Consensus About Treatment and Prevention?**
- **The Child With Stridor – Diagnosis and Management**
- **EBV: Diagnosis, Complications, and Complex Cases**
- **Impact of the Rotavirus Vaccine on Rotavirus Disease**
- **Malaria: Recognition and Management**
- **HPV Vaccine: What Have We Learned?**
- **Next Steps in Preventing Meningococcal Disease in Children**
- **Next Generation Pneumococcal Vaccines**
- **Does Probiotic Use Limit Certain Infections?**
- **New Challenges for Travelers**
- **Hectic Fevers in the First Year of Life**
- **Vaccine Safety**
- **STD Guidelines**



Target Audience: This conference is designed for pediatricians, family practitioners, general practitioners, nurse practitioners, residents, and allied health professionals.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and *Pediatric News/Family Practice News*. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of **12.25 AMA PRA Category 1 Credit(s)**™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Medical Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Application for CME credit has been filed with the American Academy of Family Physicians. **Determination of credit is pending.**

Educational Objectives: Through participation in case discussions, small group workshops, and attendance at lectures, participants will be able to:

- Apply evidence-based practices concerning immunization across the pediatric life-span
- Identify less commonly seen travel-acquired diseases
- Improve identification and treatment of various pediatric infectious diseases

Register Now!



Course Directors

Jerome O. Klein, MD
Professor of Pediatrics, Boston University School of Medicine
Visiting Physician, Boston Medical Center

Stephen I. Pelton, MD
Professor of Pediatrics, Boston University School of Medicine
Director, Section of Pediatric Infectious Diseases, Boston Medical Center

Guest Faculty

James H. Brien, DO
Associate Professor and Head, Pediatric Infectious Diseases Section
Scott White Memorial Hospital
Texas A&M University College of Medicine

Boston University School of Medicine / Boston Medical Center Faculty

Elizabeth D. Barnett, MD
Associate Professor of Pediatrics
Director, International Clinic, Section of Pediatric Infectious Diseases

Howard Bauchner, MD
Professor of Pediatrics and Public Health
Director, Division of General Pediatrics

Ellen R. Cooper, MD
Professor of Pediatrics
Medical Director, Diagnostic Evaluation Unit, Section of Pediatric Infectious Diseases

Marisol Figueira, MD
Assistant Professor of Pediatrics
Section of Pediatric Infectious Diseases

Kenneth Grundfast, MD
Chief, Department of Otolaryngology – Head and Neck Surgery
Professor and Chairman, Otolaryngology – Head and Neck Surgery

Katherine Hsu, MD, MPH
Assistant Professor of Pediatrics
Section of Pediatric Infectious Diseases

Carole H. Moloney, RN, MSN, CPNP
Clinical Instructor, Department of Pediatrics

Colin D. Marchant, MD
Associate Professor of Pediatrics
Section of Pediatric Infectious Diseases

Vishakha Sabharwal, MD
Instructor of Pediatrics

Sandra K. Schumacher, MD, MPH
Fellow, Section of Pediatric Infectious Diseases

To register, please contact:

Boston University School of Medicine Continuing Medical Education

72 East Concord Street, A305
Boston, MA, 02118

Phone: (617) 638-4605

Toll-free: (800) 688-2475

Fax: (617) 638-4905

E-mail: cme@bu.edu

Website: www.bu.edu/cme